Spark Surges After Gene Therapy Helps 3 Hemophilia Patients

  • Clotting protein levels rise as high as 30 percent of normal
  • Drug is partnered with Pfizer, now in early-stage trial

Spark Therapeutics Inc. surged the most since October after the biotechnology company said its gene therapy helped three hemophilia B patients increase clotting ability enough to stop their regular infusion treatments.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.